NCT04880291View on ClinicalTrials.gov

First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

February 8, 2022

Study Completion Date

February 8, 2022

Conditions
Kidney DiseasesDiabetic NephropathiesDiabetes ComplicationsDiabetes MellitusEndocrine System Diseases
Interventions
DRUG

GFB-024

Peripherally acting Cannabinoid-1 receptor inverse agonist monoclonal antibody

DRUG

Placebo

Matched placebo

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors
All Listed Sponsors
lead

Goldfinch Bio, Inc.

INDUSTRY